Artificial intelligence-focused healthcare technology business Gauss partnered with Cellex, a biotech company specializing in point-of-care diagnostic testing, to create the first fast COVID-19 antigen tests clients can utilize in your home.
Katie Adams –
Wednesday, September 16th, 2020
The app can also help with automated information reporting to regional health authorities and enable medical users to instantly send information to their EMR and laboratory details systems.
In April, Cellex became the very first business to make an FDA emergency use permission for its fast COVID-19 antibody test. If the antigen test its developing with Gauss is licensed by the FDA this fall, it will be the very first authorized antigen test that permits people to evaluate themselves for COVID-19 and receive fast outcomes in their home.
More short articles on digital improvement: Fitbits AFib app gets FDA clearance, will be available in October: 4 detailsThe expert skills 6 medical facility innovation leaders are focused onJefferson Health CEO Dr. Stephen Klasko joins digital health company board.
” The combination of Cellexs precise, at-home fast antigen test with Gauss mobile app provides a scalable solution to significantly reduce transmission of COVID-19 and aid society reduce the effects of the pandemic up until a vaccine is extensively offered,” Siddarth Satish, Gauss founder and CEO, said in a Sept. 16 news release. “By embedding sophisticated computer system vision algorithms within a thoughtfully-designed user experience, we can enable consumers to carry out a rapid test in their own houses simply as well as a skilled operator or a laboratory instrument — simply by using their smartphone electronic cameras.”.
Fitbits AFib app gets FDA clearance, will be readily available in October: 4 details.
To use the test, clients follow step-by-step instructions via Gauss app. After gathering a nasal swab sample and carrying out the test, the app will prompt the patient to scan their test with their smart device. Within seconds, the app will process the image with an end-to-end neural network and inform them if they checked favorable or unfavorable.
To use the test, clients follow detailed guidelines through Gauss app. After gathering a nasal swab sample and performing the test, the app will prompt the client to scan their test with their mobile phone. Within seconds, the app will process the image with an end-to-end neural network and inform them if they evaluated positive or unfavorable.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.